Search Within

Center for Hematologic Malignancies

Formats
  1. Journal Article (6192)
  2. Meeting Abstract (6164)
  3. Review (400)
  4. Book Section (216)
  5. Editorial (172)
  6. Research Letter (159)
  7. Guidelines (83)
  8. Conference Paper (70)
  9. Correspondence (61)
  10. Miscellaneous (19)
  11. Book Whole (10)
Groups
  1. Department of Medicine (11088)
  2. Hematologic Malignancies, Division of (10639)
  3. GSK Faculty (5447)
  4. Adult Leukemia (3722)
  5. Sloan Kettering Institute Faculty (3375)
  6. Hematologic Malignancies Research (3005)

More Groups

People
  1. Sergio Giralt (1069)
  2. Miguel-Angel Perales (944)
  3. Ross Levine (787)
  4. Andrew Zelenetz (785)
  5. Steven Horwitz (671)
  6. Martin Tallman (655)

More People

Years
  1. 2025 (310)
  2. 2024 (704)
  3. 2023 (877)
  4. 2022 (830)
  5. 2021 (802)
  6. 2020 (874)

More Years

Publications
  1. Blood (3413)
  2. Journal of Clinical Oncology (869)
  3. Biology of Blood and Marrow Transplantation (602)
  4. Clinical Lymphoma, Myeloma and Leukemia (304)
  5. Cancer Research (300)
  6. Haematologica (267)

More Publications

Publishers
  1. American Society of Hematology (3684)
  2. Elsevier Inc. (1668)
  3. Nature Publishing Group (1117)
  4. American Society of Clinical Oncology (918)
  5. American Association for Cancer Research (680)
  6. Wiley Blackwell (437)

More Publishers

Results (13546)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • The paradoxical effect of glucocorticoid-induced tumor necrosis factor receptor family-related gene (GITR) activation on alloreactive CD4 and CD8 T cells and the development of GVHD
    Meeting Abstract

    Muriglan, S. J.; Ramirez-Montagut, T.; Alpdogan, O.; Van Huystee, T.; Eng, J. M.; Hubbard, V. M.; Kochman, A. A.; Tjoe, K. H.; van den Brink, M. R. M.
    Biology of Blood and Marrow Transplantation (2004)

    Fulltext@MSK | Save
  • Sequential therapy with cytarabine and bismuth-213 (Bi-213)-labeled-HuM195 (anti-CD33) for acute myeloid leukemia (AML)
    Meeting Abstract

    Mulford, D. A.; Pandit-Taskar, N.; McDevitt, M. R.; Finn, R. D.; Weiss, M. A.; Apostolidis, C.; Morgenstern, A.; Divgi, C. R.; Larson, S. M.; Scheinberg, D. A.; more...
    Blood (2004)

    Fulltext@MSK | Save
  • Bismuth-labeled anti-CD33 antibody for elimination of minimal residual disease in acute myeloid leukemia
    Meeting Abstract

    Mulford, D.; Divgi, C.; Mcdevitt, M.; Sgouros, G.; Finn, R.; Larson, S.; Apostolidis, C.; Morgenstern, A.; Scheinberg, D.; Jurcic, J.
    Cancer Biotherapy and Radiopharmaceuticals (2004)

    Fulltext@MSK | Save
  • The importance of molecular phenotype in predicting overall survival in patients with relapsed or primary refractory DLBCL treated with second-line chemotherapy and ASCT
    Meeting Abstract

    Moskowitz, C. H.; Kewalramani, T.; Hamlin, P.; Nimer, S. D.; Zelenetz, A. D.; Teruya-Feldstein, J.
    Blood (2004)

    Fulltext@MSK | Save
  • Routine imaging identifies a group of patients with more favorable aggressive NHL at relapse: A retrospective study of a uniformly treated patient population
    Meeting Abstract

    Liedtke, M.; Moskowitz, C. H.; Hamlin, P. A.; Zelenetz, A. D.
    Blood (2004)

    Fulltext@MSK | Save
  • Impact of course of therapy on response rate and duration with the Bexxar® therapeutic regimen (tositumomab and iodine I 131 tositumomab) and with chemotherapy
    Meeting Abstract

    Leonard, J. P.; Zelenetz, A. D.; Vose, J. M.; Kaminski, M. S.
    Blood (2004)

    Fulltext@MSK | Save
  • Long term complications from treatment in survivors of high risk neuroblastoma
    Meeting Abstract

    Laverdiere, C.; Cheung, N. K. V.; Kushner, B. H.; Kramer, K.; Modak, S.; La Quaglia, M. P.; Wolden, S.; Ness, K. K.; Gurney, J. G.; Sklar, C. A.
    Journal of Clinical Oncology (2004)

    Fulltext@MSK | Save
  • Pentostatin and cyclophosphamide with or without rituximab has significant activity in patients with previously treated chronic lymphocytic leukemia and other low grade lymphoid neoplasms
    Meeting Abstract

    Lamanna, N.; Kalaycio, M.; Maslak, P.; Jurcic, J.; Scheinberg, D. A.; Gencarelli, A. N.; Horgan, D.; Weiss, M. A.
    Blood (2004)

    Fulltext@MSK | Save
  • Intrathecal 131-I-labeled 3F8 antibody in patients with GD2-expressing central nervous system and leptomeningeal neoplasms
    Meeting Abstract

    Kramer, K.; Cheung, N. K. V.; Humm, J.; Yeh, S.; Dantis, E.; Dunkel, I. J.; Wolden, S.; Finn, R.; Kushner, B. H.; Khakoo, Y.; more...
    Neuro-Oncology (2004)

    Fulltext@MSK | Save
  • Tositumomab and iodine I 131 tositumomab (BEXXAR (R) therapeutic regimen) produces long-term durable responses in heavily pretreated patients with relapsed, refractory, and transformed low-grade non-hodgkin's lymphoma (NHL
    Meeting Abstract

    Knox, S. K.; Meredith, R. F.; Coleman, M.; Kaminski, M. S.; Zelenetz, A. D.; Vose, J. M.
    International Journal of Radiation Oncology, Biology, Physics (2004)

    Fulltext@MSK | Save